Regulatory FDA Ties Amgen’s Rare Inflammatory Disease Drug to Eight Deaths, Dozens of Liver Injuries BioSpaceThe FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug's overall risk-benefit profile.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) BioSpace The FDA in January asked Amgen to pull Tavneos from the market, citing liver toxicity issues that affected the drug’s overall risk-benefit profile. RegulatoryImmunology & InflammationRead full story Post navigation Previous: IO Shuts Down Following Regulatory RoadblocksNext: Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B Related Stories Regulatory Third Circuit Affirms Denial of Stelara Biosimilar Injunction pharminent May 11, 2026 Regulatory Partner’s Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher pharminent May 11, 2026 Regulatory BMS’ Sotyktu secures EC approval for psoriatic arthritis pharminent May 11, 2026
